

TABLE OF CONTENTS

February 11, 2008

No. 2077

BUSINESS

- 1 Chugai' Sunrise 2012 Plan Calls For Sales of ¥460 Bil.
- Applications to Be Filed for 4 New Drugs, 10 Line Extensions by 2013
- Anticancer Drugs Show Strong Growth
- Operating Profits to Decrease by Half in 2008
- 3 **Stop Press**
- Takeda Acquires Amgen in Japan
- 3 **NEW PRODUCTS**
- Bayer Launches EOB Primovist for MRI of the Liver
- 4 Mediceo Paltac to Embark on Generics Business in Earnest
- Aiming at Share of 30% in the Market for Dispensing Pharmacies
- 5 Shigeo Oyagi Elected President, CEO of Teijin Limited
- Teijin Pharma Appoints Osamu Nishikawa as Successor
- 4 **BUSINESS NEWS IN BRIEF**
- Eisai Completes Acquisition of MGI Pharma
- Abbott, Eisai Change Sales Scheme for Adalimumab
- Abbott, Eisai to Develop Additional Indications for Adalimumab

REGULATORY

- 6 All ARBs, SSRIs to Be Re-priced
- 7 Repeat Consultation Fee for Clinics Will Not Be Cut: *Chuikyo*
- Revised NHI Pricing Rule Finalized
- 8 **Commentary**
- Revision of Medical Fees May Increase Use of Drugs for Stroke, Mental Illnesses, Cancer
- 9 Actemra to Be Approved for RA
- 10 **REGULATORY NEWS IN BRIEF**
- Daiichi Sankyo's Gracevit Approved
- DSP's Lonasen Approved for the Treatment for Schizophrenia
- Nexavar, Zevalin from Bayer Yakuhin Approved
- Singulair/Kipres Approved for Allergic Rhinitis in Adults
- Asahi Kasei's Licomodulin Approved
- Pfizer's Revatio, Champix Approved
- Sanofi-aventis' Clexane Approved

- Amerge from GSK Approved to Treat Migraines

COMMENTARY

- 12 Current New Drug Development in the Japanese Pharmaceutical Industry: Keiji Nakamura, Ph. D.

R&D

- 19 Japan Should Take Part in More Multinational Clinical Trials: JMACCT Conference
- Serious Concern Expressed about Japan's Low Participation Rate
- Poor English Skills Is a Problem
- Quality of PI Facilities Should Be Improved in Japan: Mr Mori of PMDA
- Experience of 3 Companies Indicates that "It's Possible also in Japan"
- Question Is if Japan's Participation Will Pay or Not
- 20 Live Vaccine Development Important for New-type Influenza
- Collaboration of Industry, Government and Academia Needed to Commercialize Vaccines
- 21 **R&D NEWS IN BRIEF**
- Otsuka Obtains Rights to New Peptide Vaccines from OTS
- Kyorin, Merck Collaborate to Find Anti-infectious Drugs
- ClioScience Embarks on CRO Business in China through China Gate
- Adair Improves QOL and Survival Benefits: GSK

MEDICAL FACILITIES & NURSING CARE

- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
- Zyrtec/Flunase Combination Shows High Patient Satisfaction Rate for Pollinosis
- 70 More Hospitals Designated as Base Hospitals for Cooperation in Cancer Therapy
- *Koroshō* to Deal with Shortage of Doctors
- National Burden Rate Up 0.1 Points to 40.1% in FY2008

TOPICS

- 23 **TOPICS**
- Merck Seiyaku Renamed Mylan Seiyaku